Back to News
Market Impact: 0.2
Bolt Biotherapeutics Consensus Price Target Increased by 1,400% to $76.50
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
The average one-year analyst price target for Bolt Biotherapeutics was revised to $76.50 per share, up 1,400.00% from the prior $5.10 estimate dated October 20, 2026. The figures are an aggregate of analyst targets; the article text provides no further context or reported market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BOLT0.50
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- RA Capital Management sells $9.13M in Lenz Therapeutics shares